SciClone Reports 2012 Financial Results and 2013 Outlook

SciClone Reports 2012 Financial Results and 2013 Outlook 
Company Completes Restatement of Prior Periods 
FOSTER CITY, CA -- (Marketwire) -- 04/01/13 --  SciClone
Pharmaceuticals, Inc. (NASDAQ: SCLN) today reported financial results
for the fourth quarter and for the year ended December 31, 2012.  
Overall revenues increased $23.7 million or 18% for the full year
2012 to $156.3 million, compared to $132.6 million for the prior
year, including a $7.3 million or 7% increase in sales of ZADAXIN(R).
In the fourth quarter of 2012, ZADAXIN sales decreased $8.9 million,
or 30% for the quarter, and overall sales decreased $6.5 million or
16% for the quarter, compared to the same period of the prior year.
As discussed previously, during the third quarter and particularly in
September 2012, the Company estimates there was an increase in
ZADAXIN channel inventory levels, and believes that sales to its
customers (including importers and distributors) exceeded the pace at
which those customers were able to sell ZADAXIN through to other
parties, primarily hospital pharmacies, and that channel inventory
build-up of ZADAXIN also impacted fourth quarter ZADAXIN revenues.
ZADAXIN channel inventory levels improved significantly in the fourth
quarter of 2012, and the Company expects these levels to continue to
improve in the first half of 2013 to more typical levels for imported
drugs as the Company continues to expand market penetration and grow
demand for ZADAXIN. 
Commented Friedhelm Blobel, Ph.D., SciClone Chief Executive Officer:
"In the fourth quarter, while we saw the impact on our revenue from
the ZADAXIN(R) channel inventory build-up that occurred primarily in
the third quarter of last year, we also continued to make good
progress in implementing important personnel, strategic, and
operational improvements designed to reestablish the foundation for
our continued revenue and profitability growth. Key to our progress
has been strengthening our organization with new senior management in
China and a re-energized ZADAXIN sales force committed to achieving
our growth and financial goals while maintaining our commitment to
act in compliance with all legal and regulatory requirements. We
believe we are emerging from our second-half 2012 challenges as a
stronger and more execution-focused company. We believe that our
business fundamentals remain strong, and that our excellent cash
position at the end of 2012 is an important asset that provides
significant flexibility to accomplish our growth objectives."  
Continued Dr. Blobel: "Our top priorities for 2013 and beyond are to
continue to execute on our strategy to reestablish SciClone's growth
trajectory: to implement our strategies for long-term growth of
ZADAXIN; to expand Depakine sales and build momentum for potential
market leaders, such as Aggrastat(R); to enhance the quality and
performance of our organization; to establish profitability in our
product promotion business; to seek new product in-licensing
opportunities to drive long-term growth; and to strengthen our
position within the China pharmaceutical market." 
The Company also announced the completion of its restatement for each
of the first, second and third quarters of 2012 and for each of the
second and third quarters of 2011 and for the year ended December 31,
2011 with the Company's Form 10-K for the period ended December 31,
2012 and Form 10-Q/As for the periods ended March 31, June 30 and
September 30, 2012, each filed with the Securities and Exchange
Commission today. The financial results in this press release reflect
SciClone's financial results on a restated basis. As previously
disclosed, the restatement primarily related to accounting errors
within the Company's subsidiary NovaMed in China pertaining to the
timing of Pfizer product revenue recognition and the recognition of
product return reserves as to Aggrastat. Further information about
the restatement is contained in the Company's Form 10-K for the
period ended December 31, 2012. Comparable periods in 2011 referred
to in this press release include the financial results of NovaMed
only for the period subsequent to the acquisition of NovaMed on April
18, 2011. 
Financial Results 
Revenues increased by 18% for the full year of 2012 to $156.3
million, compared to revenues in the prior year of $132.6 million.
SciClone reported that revenues decreased by 16% for the fourth
quarter ended December 31, 2012 to $33.1 million, compared to
revenues for the same period in the prior year of $39.7 million.  
The increase in revenues for the full year and the decrease in
revenues in the fourth quarter were also affected by the inclusion of
the NovaMed primary care and oncology business revenues since the
date of the acquisition. For the full year 2012, ZADAXIN revenues
increased 7% to $112.2 million compared to prior year ZADAXIN
revenues of $104.8 million, and revenues attributable to the primary
care and oncology product lines increased 59% to $44.1 million for
the full year 2012, compared to prior year revenues of $27.7 million.
For the fourth quarter of 2012, ZADAXIN revenues decreased 30% to
$20.8 million compared to revenues for the same period in the prior
year of $29.7 million, and revenues attributable to the primary care
and oncology product lines increased $2.3 million to $12.3 million
for the fourth quarter of 2012, compared to $10.0 million for the
same period in the prior year.  
On a pro forma basis, assuming NovaMed had been acquired on January
1, 2011, revenues for the full year 2012 of $156.3 million would have
been compared to revenues of $140.6 million in the prior year, an
increase of $15.7 million or 11%.  
On a GAAP basis, SciClone's net income for the full year 2012 was
$9.6 million, compared with $28.1 million for the prior year, or
$0.17 and $0.16 per share on a basic and diluted basis, respectively,
compared with $0.51 and $0.49 per share on a basic and diluted basis,
respectively, for the prior year. The decrease in per share net
income for the 2012 annual period included a one-time, non-cash
impairment charge of approximately $42.7 million, offset in part by
certain non-cash gains, which related to the NovaMed acquisition.
SciClone's net income for the fourth quarter of 2012 was $1.9
million, compared with net income of $11.6 million for the same
period in the prior year, or net income of $0.03 per share on both a
basic and diluted basis for the fourth quarter of 2012, compared with
net income of $0.20 and $0.19 per share on a basic and diluted basis,
respectively, for the same period in the prior year.  
SciClone's non-GAAP net income for the full year 2012, was $36.7
million, compared with non-GAAP income of $34.0 million last year, or
$0.65 and $0.63 per share on a basic and diluted basis, respectively,
for the full year 2012, compared to $0.62 and $0.59 per share on a
basic and diluted basis, respectively, in the prior year. SciClone's
non-GAAP net income for the fourth quarter of 2012 was $2.0 million,
compared with non-GAAP income of $11.4 million for the same period in
the prior year, or $0.04 per share on both a basic and diluted basis
for the fourth quarter of 2012, and $0.19 per share on both a basic
and diluted basis for the same period in the prior year.  
SciClone believes this non-GAAP information is useful for investors,
taken in conjunction with SciClone's GAAP financial statements,
because management uses such information internally for its
operating, budgeting and financial planning purposes. Non-GAAP
information is not prepared under a comprehen
sive set of accounting
rules and should only be used to supplement an understanding of
SciClone's operating results as reported under GAAP. The non-GAAP
calculations and reconciliation to comparable GAAP measures were
derived principally as a result of the NovaMed acquisition and are
provided in the accompanying table titled "Reconciliation of GAAP to
Non-GAAP Net Income." 
Sales and marketing expenses for the full year 2012 were $70.3
million, compared with $48.9 million in the prior year. Sales and
marketing expenses for the fourth quarter of 2012 were $18.1 million,
compared with $15.8 million for the same period in the prior year.
The increase of $21.4 million for the year and $2.3 million for the
fourth quarter was primarily a result of expansion in China
operations, and for the full year, related to the acquisition of
NovaMed in April 2011.  
Research and development (R&D) expenses for the full year 2012 were
$6.1 million, compared with $12.3 million in the prior year. R&D
expenses for the fourth quarter of 2012 totaled $0.4 million,
compared with $3.1 million for the same period in the prior year. R&D
expenses decreased for the year and fourth quarter primarily as a
result of the Company's reduction of its US-based clinical
development expenses following the Company's announcement on March 2,
2012 regarding the futility of its SCV-07 clinical development
program in oral mucositis. The Company expects further decreases in
R&D expenses in 2013.  
General and administrative expenses for the full year 2012 were $21.4
million, compared with $24.0 million in the prior year. General and
administrative expenses for the fourth quarter of 2012 were $7.4
million, compared with $4.6 million for the same period in the prior
year. The decrease in 2012 and increase for the fourth quarter were
primarily due to fluctuations in professional services expenses
related to legal and accounting matters associated with the ongoing
government investigations and NovaMed internal control matters, and
related to $3.8 million in NovaMed acquisition-related transaction
fees in 2011 incurred in the first three quarters. 
At December 31, 2012, cash and cash equivalents, restricted cash, and
investments totaled $87.0 million, compared with $67.0 million at
December 31, 2011. The increase in SciClone's cash balance was
primarily due to the cash generated by the Company's commercial
operations, partially offset by $24.8 million used in the year ended
December 31, 2012 for the repurchase of SciClone stock. 
Financial Outlook for 2013 
SciClone anticipates 2013 revenues between $150 and $155 million.
SciClone expects that ZADAXIN revenues will be lower in the first
half of 2013 related to the current levels of ZADAXIN channel
inventory resulting from the previous build-up, compared to the first
half of 2012, and believes that ZADAXIN revenues will increase in the
second half of 2013, compared to the first half of 2013.  
The Company expects non-GAAP earnings per share for the full year
2013 to be between $0.66 and $0.72. SciClone cash and investments at
December 31, 2013 are projected to be greater than $105 million,
excluding the cash impact of any future repurchases of common stock
from its remaining $9.9 million share repurchase plan.  
SciClone's non-GAAP EPS forecast for 2013 excludes employee
stock-based compensation and other expenses described in the
Company's reconciliation of GAAP to non-GAAP income, which the
Company is not able to reasonably estimate at this time for the full
fiscal year. 
Conference Call Today 
SciClone is hosting a conference call today at 4:30 pm ET to provide
a financial update. The call will be hosted by Friedhelm Blobel,
Ph.D., President and CEO, Gary Titus, Senior Vice President and CFO.  
LIVE CALL: 
 877 299 4454 (U.S./Canada)
 617 597 5447
(International)
 Passcode: 11945575 
REPLAY: 
 888 286 8010 (U.S./Canada)
 617 801 6888 (International) 
Passcode: 95860527 
 (Replay available from Monday, April 1, 2013, at
6:30 pm ET until 11:59 pm ET on Monday, April 8, 2013) 
The conference call will contain forward-looking statements.
Interested parties who wish to listen to the webcast should visit the
Investor Relations section of SciClone's website at www.sciclone.com.
The information provided on the teleconference is accurate only at
the time of the conference call, and SciClone will take no
responsibility for providing updated information except as required
by law.  
About SciClone  
SciClone Pharmaceuticals is a revenue-generating, profitable,
specialty pharmaceutical company with a substantial commercial
business in China and a product portfolio of therapies for oncology,
infectious diseases and cardiovascular, urological, respiratory, and
central nervous system disorders. SciClone's ZADAXIN(R) (thymalfasin)
is approved in over 30 countries and may be used for the treatment of
hepatitis B (HBV), hepatitis C (HCV), and certain cancers, and as a
vaccine adjuvant, according to the local regulatory approvals.
Besides ZADAXIN, SciClone markets about 14 mostly partnered products
in China, including Depakine(R), the most widely prescribed
broad-spectrum anti-convulsant in China; Tritace(R), an ACE inhibitor
for the treatment of hypertension; Stilnox(R), a fast-acting hypnotic
for the short-term treatment of insomnia (marketed as Ambien(R) in
the US); and Aggrastat(R), a recently-launched interventional
cardiology product. SciClone is also pursuing the registration of
several other therapeutic products in China. SciClone is
headquartered in Foster City, California. For additional information,
please visit www.sciclone.com.  
Forward-Looking Statements  
This press release contains forward-looking statements regarding
expected financial results and expectations. Readers are urged to
consider statements that include the words "may," "will," "would,"
"could," "should," "might," "believes," "estimates," "projects,"
"potential," "expects," "plans," "anticipates," "intends,"
"continues," "forecast," "designed," "goal," "unaudited,"
"approximately" or the negative of those words or other comparable
words to be uncertain and forward-looking. These statements are
subject to risks and uncertainties that are difficult to predict and
actual outcomes may differ materially. These include risk and
uncertainties relating to: the course, cost and outcome of regulatory
matters, including further pricing decisions by authorities in China;
the on-going regulatory investigations; the Company's ability to
execute on its goals in China and on its objectives for revenue in
fiscal 2013; the challenges presented by integrating an acquired
business into existing operations; the effect of management changes
and turnover in its China operations; the potential effect over the
coming quarters of increased channel inventory, the dependence on
third-party license, promotion or distribution agreements including
the need to renew such agreements or end arrangements that the
Company does not believe are beneficial; operating an international
business; the clinical trial process, including the regulatory
approval and the process of initiating trials at, and enrolling
patients at, clinical sites; the effect of changes in its practices
and policies related to the Company's compliance programs. SciClone
cannot predict the timing or outcome of the ongoing SEC and DOJ
investigations, or of the level of its efforts required to cooperate
with those investigations, however the Company has incurred
substantial expenses in connection with the investigations and
related litigation and expects to incur substantial additional
expense and the investigations could result in fines and further
changes in its internal control or other remediation measures that
could adversely affect its business. Please also refer to other risks
and uncertainties described in SciClone's filings with the SEC. All
forward-looking statements are based on information currently
available to SciClone and SciClone assumes no obligation to update
any such forward-looking statements.  
Ambien, Depakine, Stilnox and Tritace are registered trademarks of
Sanofi and/or its affiliates. 
Aggrastat is a registered trademark of Medicure International Inc. in
the United States, and Iroko Cardio LLC in numerous other countries. 
SciClone, SciClone Pharmaceuticals, the SciClone Pharmaceuticals
design, the SciClon
e logo and ZADAXIN are registered trademarks of
SciClone Pharmaceuticals, Inc. in the United States and numerous
other countries. 


 
                                                                            
                                                                            
                       SCICLONE PHARMACEUTICALS, INC.                       
                UNAUDITED CONSOLIDATED STATEMENTS OF INCOME                 
                  (in thousands, except per share amounts)                  
                                                                            
                               Three Months Ended          Year Ended       
                                  December 31,            December 31,      
                             ----------------------  ---------------------- 
                                          Restated                Restated  
                                 2012       2011         2012       2011    
                              ---------  ----------   ---------  ---------- 
                                                                            
 Net revenues:                                                              
  Product sales              $   24,587  $   31,772  $  123,171  $  111,951 
  Promotion services              8,552       7,903      33,098      20,614 
                              ---------   ---------   ---------   --------- 
    Total net revenues           33,139      39,675     156,269     132,565 
                                                                            
 Operating expenses:                                                        
  Cost of product sales           5,326       5,839      21,996      19,409 
  Sales and marketing            18,120      15,796      70,327      48,853 
  Amortization of acquired                                                  
   intangible assets,                                                       
  related to sales and                                                      
   marketing                          -         893       2,645       2,465 
  Research and development          393       3,111       6,143      12,346 
  General and administrative      7,353       4,613      21,442      24,032 
  Intangible asset                                                          
   impairment                         -           -      42,728           - 
  Contingent consideration         (562)     (2,072)    (15,422)     (3,495)
                              ---------   ---------   ---------   --------- 
    Total operating expenses     30,630      28,180     149,859     103,610 
                              ---------   ---------   ---------   --------- 
                                                                            
 Income from operations           2,509      11,495       6,410      28,955 
                                                                            
 Non-operating income                        
                               
 (expense):                                                                 
  Interest income                    16          23          89          71 
  Interest expense                  (18)        (54)       (185)       (213)
  Other (expense) income,                                                   
   net                              (20)        (27)        (42)        (21)
                              ---------   ---------   ---------   --------- 
 Income before provision for                                                
 income tax                       2,487      11,437       6,272      28,792 
 Provision (benefit) for                                                    
 income tax                         599        (113)     (3,348)        670 
                              ---------   ---------   ---------   --------- 
 Net income                  $    1,888  $   11,550  $    9,620  $   28,122 
                              =========   =========   =========   ========= 
                                                                            
 Basic net income per share  $     0.03  $     0.20  $     0.17  $     0.51 
 Diluted net income per                                                     
 share                       $     0.03  $     0.19  $     0.16  $     0.49 
                                                                            
 Weighted a
verage shares                                                    
 used in computing:                                                         
  Basic net income per share     55,007      58,274      56,637      55,110 
  Diluted net income per                                                    
   share                         56,471      59,976      58,483      57,387 
                                                                            
                                                                            
                       SCICLONE PHARMACEUTICALS, INC.                       
                RECONCILIATION OF GAAP TO NON-GAAP NET INCOME               
                  (in thousands, except per share amounts)                  
                                 (unaudited)                                
                                                                            
                                      Three Months Ended      Year Ended    
                                         December 31,        December 31,   
                                     ------------------- -------------------
                                                Restated            Restated
                                        2012      2011      2012      2011  
                                     --------- --------- --------- ---------
                                                       
                     
GAAP net income                      $   1,888 $  11,550 $   9,620 $  28,122
Non-GAAP adjustments:                                                       
  Employee stock-based compensation        709       978     3,897     3,108
  Amortization of acquired                                                  
   intangible assets                         -       893     2,645     2,465
  Intangible assets impairment               -         -    42,728         -
  Contingent consideration               (562)   (2,072)  (15,422)   (3,495)
  Net tax benefit related to                                                
    NovaMed deferred tax assets                                             
    and liabilities                          -         -   (6,800)         -
  Acquisition related costs                  -         8         -     3,818
                                     --------- --------- --------- ---------
    Non-GAAP net income              $   2,035 $  11,357 $  36,668 $  34,018
                                     ========= ========= ========= =========
                                                                            
                                                                            
Non-GAAP basic net income per share  $    0.04 $    0.19 $    0.65 $    0.62
Non-GAAP diluted net income per                                             
 share                               $    0.04 $    0.19 $    0.63 $    0.59
                                                                            
Weighted average shares used in                                             
 computing:                                                                 
Non-GAAP basic net income per share     55,007    58,274    56,637    55,110
Non-GAAP diluted net income per                                             
 share                                  56,471    59,976    58,483    57,387

 
SciClone management uses these non-GAAP financial measures to monitor
and evaluate the Company's operating results and trends on an
on-going basis and internally for operations, budgeting and financial
planning purposes. SciClone believes the non-GAAP information is
useful for investors by offering them the ability to better
understand how management evaluates the business. These non-GAAP
measures have limitations, however, because they do not include all
items of income and expenses that affect SciClone. These non-GAAP
financial measures that management uses are not prepared in
accordance with, and should not be considered in isolation of, or as
an alternative to, measurements required by GAAP. 
SciClone's non-GAAP financial measures exclude the following items
from GAAP net income (loss) and net income (loss) per
 share: 


 
--  Employee stock-based compensation. The effects of non-cash employee
    stock-based compensation.
--  Amortization of acquired intangible assets. We recorded intangible
    assets in connection with the acquisition of NovaMed. The amortization
    of these intangible assets is excluded from SciClone's non-GAAP
    financial measure.
--  Intangible assets impairment. We recorded a one-time non-cash
    impairment loss to fully write-down the intangible assets acquired in
    connection with the acquisition of NovaMed. The impairment loss on
    these intangible assets is excluded from SciClone's non-GAAP financial
    measure.
--  Contingent consideration. The contingent consideration related to the
    acquisition of NovaMed is re-measured each reporting period and the
    change in fair value is recorded as an adjustment to operating
    expense. SciClone's non-GAAP financial measure excludes the change in
    fair value of the liability for contingent consideration in connection
    with the acquisition of NovaMed.
--  Net tax benefit related to NovaMed deferred tax assets and
    liabilities. We recorded a non-cash net tax benefit related to
    NovaMed, primarily due to the impairment of intangible assets, which
    resulted in reversal of related deferred tax liabilities, and the
    impact of recording a full valuation allowance on any remaining
    NovaMed deferred tax assets.
--  Acquisition related costs. We incurred certain one-time acquisition
    costs related to the acquisition of NovaMed. The effects of these
    acquisition related costs are excluded from SciClone's non-GAAP
    financial measure.

 
                                                                            
                                                                            
                       SCICLONE PHARMACEUTICALS, INC.                       
                    UNAUDITED SELECTED BALANCE SHEET DATA                   
                               (in thousands)                               
                                                                            
                                                               December 31, 
                                               December 31,        2011     
                                                   2012          Restated   
                                             --------------- ---------------
                                                                            
Cash and investments                         $        84,228 $        66,654
Restricted cash and investments                        2,759             364
Accounts receivable                                   38,109          38,465
Inventories                                           10,424          11,141
Intangible assets, net                                     -          45,185
Goodwill                                              34,313          33,868
Total assets                                         174,071         200,844
Total current liabilities                             30,812          26,449
Contingent consideration                                   -          15,400
Deferred tax liabilities                                 153           8,407
Short-term borrowings                                  1,445           2,500
Total shareholders' equity                           143,022         150,119

  
Corporate Contacts 
Gary Titus 
Chief Financial Officer
650.358.3456 
gtitus@sciclone.com  
Jane Green 
Investors/Media
650.358.1447
jgreen@sciclone.com 
 
 
Press spacebar to pause and continue. Press esc to stop.